Submission of the manuscript is online via e-mail or

Tel: +7 903 250 5288

Editorial Correspondence e-mail

Publishing, Subscriptions, Sales and Advertising, Correspondence e-mail

Tel: +7 917 561 9505

SCImago Journal & Country Rank

    1. Multidisciplinary medical center of the Central Bank of the Russian Federation (Moscow, Russian Federation)

    Keywords:esophageal-gastric junction,cardia,diaphragmatic constriction,metaplastic mucosa,Barrett’s esophagus,hiatal hernia

    Abstract:Endoscopic picture of esophageal-gastric junction in normal and pathological conditions is still a matter of attention of domestic and international medical community: endoscopists, gastroenterologists, morphology, as well as abdominal and thoracic surgeons. Endoscopic semiotics and target biopsy of pathological focus are the basis for the diagnosis and definition of further tactics for the patient. The main issues addressed in the review 1.Anatomical Z-line position relative to the outlet of the cardia and diaphragma 2. Histological features of esophageal-gastric junction in normal 3. Options endoscopic picture in normal and in condition of metaplastic mucosa 4. The endoscopic picture with hiatal hernia

      1. Руководство Американской гастроэнтерологической ассоциации по лечению ГЭРБ, 2008
      2. Руководство Общества американских гастроэнтерологов и эндоскопических хирургов по хирургическому лечению ГЭРБ, 2010
      3. Медикаментозное и хирургическое лечение ГЭРБ, систематический обзор 2010
      4. Руководство Британского гастроэнтерологического общества по диагностике и ведению пациентов с пищеводом Барретта, 2013
      5. Рандомизированное исследование LOTUS, 5-летнее наблюдение (Galmiche et al., 2011)
      6. Дронова О. Б. Анатомо-эндоскопические и клинико-функциональные основы гастроэзофагеальной рефлюксной болезни: Дисс. на соискание ученой степени д. м. н., 2008.
      7. Колесников Л. Л. Сфинктерный аппарат человека. СПб.: Специальная литература - 2000-184 с. - Монография.
      8. Маржатка З., Поддубный Б. К., Федоров Е. Д. Эндоскопия пищеварительного тракта Номенклатура OMED, Третье издание, 1996 г.

    Full text is published :
    Read & Download full text

    1. Federal State Budget Educational Institution of Higher Education «Samara State Medical University» of the Ministry of Health of the Russian Federation (Samara, Russian Federation)

    Keywords:Refractory to inhibitors of proton pump gastroesophageal reflux disease,diagnosis,treatment

    Abstract:Aim of the review. At a modern scientific level, to illuminate the problem of refractory to proton pump inhibitors (PPI) forms of gastroesophageal reflux disease (RFGERD). It is shown that PPI remain the standard and most effective therapy for gastroesophageal reflux disease (GERD). Patients in whom GERD symptoms are refractory to PPI should be further examined to exclude other diseases. It is possible to use different treatment options: medication, endoscopic or surgical. The response to IPP therapy can be complete (no symptoms), partial or absent. In patients with a full response to treatment with PPI, no other treatment is foreseen. Patients with partial response may require endoscopic or surgical intervention. Currently, new methods of conservative therapy of RFGERD are being actively developed. Special hopes for improvement of the symptoms of RFGERD are currently associated with the means that can provide visceral analgesia.

      1. Старостин Б. Д. Гастроэзофагеальная рефлюксная болезнь (часть I). Эпидемиология, факторы риска. Гастроэнтерология Санкт-Петербурга. 2014; 1(2):2-14.
      2. Sifrim D. Acid, weakly acidic and non-acid gastro-oesophageal reflux. Eur J Gastroenterol Hepatol. 2004; 16:823-830.
      3. Fass R., Gasiorowska A. Refractory GERD: what is it? Curr Gastroenterol Rep. 2008; 10:252-257.
      4. Sharma N., Agrawal A., Freeman J. et al. An analysis of persistent symptoms in acid-suppressed patients undergoing impedance-pH monitoring. Clin Gastroenterol Hepatol. 2008; 6:521-524.
      5. Aziz Q., Fass R., Gyawali C. P. et al. Esophageal disoders. Gastroenterology. 2016; 150:1368-1379.
      6. Shapiro M., Green C., Bautista J. M. et al. Functional heartburn patients demonstrate traits of functional bowel disorder but lack a uniform increase of chemoreceptor sensitivity to acid. Am J Gastroenterol. 2006; 101:1084-1091.
      7. Yoshida N., Kuroda M., Suzuki T. et al. Role of nociceptors/neuropeptides in the pathogenesis of visceral hypersensitivity of nonerosive reflux disease. Dig. Dis. Sci. 2012; 58:2237-2243.
      8. Fass R., Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut. 2009; 58:295-309.
      9. Todd J. A., Basu K. K., de Caestecker J. S. Normalization of oesophageal pH does not guarantee control of duodenogastro-oesophageal reflux in Barrett’s oesophagus. Aliment Pharmacol Ther. 2005; 21:969-975.
      10. Farre R., Van Malenstein M. H., de Vos R. et al. Weakly acidic solutions containing pepsin and bile acids can increase significantly esophageal mucosa permeability (abstract). Gastroenterology. 2007; 132(4 Suppl 2): S 1897.
      11. Peghini P. L., Katz P. O., Bracy N. A. et al. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol. 1998; 93:763-767.
      12. Dammann H. G., Fuchs W., Richter G. et al. Lansoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion. Aliment Pharmacol Ther. 1997; 11:359-364.
      13. Leite L., Lambrecht N., Sachs G. et al. Is omeprazole resistance due to mutations of cysteine 813 or 822 in the acid pump? (abstract). Gastroenterology. 1995;108: A147.
      14. Chiba N., De Gara C. J., Wilkinson J. M. et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997; 112:1798-1810.
      15. Давыдкин И. Л. Осадчук А. М. Бородулина Е. А. Гриценко Т. А. Инфильтративный туберкулез легких, язвенная болезнь и ВИЧ-инфекция (коморбидность и мультиморбидность заболеваний). Наука и инновации в медицине. 2016; 1:19-24.
      16. Holtmann G., Cain C., Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology. 1999; 117:11-16.
      17. Mizyed I., Fass S. S., Fass R. Review article: gastro-oesophageal reflux disease and psychological comorbidity. Aliment Pharmacol Ther. 2009; 29:351-358.
      18. Rohof W. O., Bennink R. J., de Jonge H. et al. Increased proximal reflux in a hypersensitive esophagus might explain symptoms resistant to proton pump inhibitors in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2014;12:1647-1655.
      19. Осадчук М. А., Осадчук А. М., Балашов Д. В., Кветной И. М. Рефрактерная форма гастроэзофагеальной рефлюксной болезни: клинико-эндоскопические, функциональные и морфофункциональные критерии. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2011; 2: 30-37.
      20. Гриценко Т. А., Давыдкин И. Л., Осадчук А. М., Косталанова Ю. В. Гастроэзофагеальная рефлюксная болезнь у пациентов, получающих полихимиотерапию: клинические, эндоскопические, морфологические и иммуногистохимические особенности. Экспериментальная и клиническая гастроэнтерология. 2015;2(114):17-23.
      21. Becker V. Positive predictors for gastroesophageal reflux disease and the therapeutic response to proton-pump inhibitors. World J Gastroenterol. 2014; 20:4017-4024.
      22. Хуболов А. М., Толстокоров А. С., Коваленко Ю. В. Результаты антирефлюксной хирургической коррекции грыж пищеводного отверстия диафрагмы у лиц пожилого и старческого возраста. Аспирантский вестник Поволжья. 2016; 1(2): 167-171.
      23. Chowers Y., Atarot T., Pratha V. S. et al. The effect of once daily omeprazole and succinic acid (VECAM) vs. once daily omeprazole on 24-h intragastric pH. Neurogastroenterol Motil. 2012; 24:426-431.
      24. Vela M. F., Tutuian R., Katz P. O. et al. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther. 2003;17:243-251.
      25. Adachi K., Furuta K., Miwa H. et al. A study on the efficacy of rebamipide for patients with proton pump inhibitor-refractory non-erosive reflux disease. Dig Dis Sci. 2012; 57:1609-1617.
      26. Maradey-Romero C., Fass R. New and future drug development for gastroesophageal reflux disease. J Neurogastroenterol Motil. 2014; 20:6-16.

    Full text is published :
    Osadchuk A.M., Davydkin I.L., Gricenko T.A., Kurtov I.V. et al. REFRACTORY TO PROTON PUMP INHIBITORS GASTROESOPHAGEAL REFL UX DISEASE. Experimental and Clinical Gastroenterology Journal. 2017;144(08):55-61
    Read & Download full text